NERLYNX: The Power to Reduce the Risk of Progression
"Metastatic" means that the cancer has spread beyond the breast and nearby lymph nodes to other parts of the body. NERLYNX is taken with capecitabine (an oral chemotherapy) to help prevent the cancer from spreading any further.
NERLYNX is intended for people with HER2+ mBC who have already been treated with 2 or more HER2-directed therapies for mBC. These may include trastuzumab, T-DM1, and/or pertuzumab (Herceptin®, Kadcyla® and/or Perjeta®).
Download a NERLYNX brochure
Your resource to help you get started on treatment.
The Benefits of NERLYNX + Capecitabine
NERLYNX was studied in a clinical trial of 621 people who had HER2+ mBC and had undergone treatment with 2 or more HER2-directed treatments for mBC. The trial compared people who took NERLYNX plus capecitabine with people who took lapatinib (Tykerb®) plus capecitabine. Participants were randomly selected to receive NERLYNX.
In the clinical trial, NERLYNX plus capecitabine reduced the risk of cancer progressing.*
In the clinical trial, NERLYNX also gave people a longer response to treatment compared with lapatinib plus capecitabine.†
Be confident in knowing you have the power to help reduce the risk of progression with NERLYNX.
*These are relative benefits. In absolute numbers, at 12 months, the progression-free survival rate was 29% in the NERLYNX plus capecitabine group vs 15% in the lapatinib plus capecitabine group.
†Median of 8.5 months compared to 5.6 months for those taking lapatinib (Tykerb®). The 8.5 and 5.6 months durations were calculated only from the percentage of people that responded to therapy (32.8% in the NERLYNX group vs 26.7% in the lapatinib group).
If you are considering or have started treatment, and have questions about what to expect, speak with a mentor.Connect now